Spanlecortemlocel
- Generic Name
- Spanlecortemlocel
- Drug Type
- Biotech
- Unique Ingredient Identifier
- D8O38M043D
MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Magenta Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03406962
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD)
Phase 1
Withdrawn
- Conditions
- Inherited Metabolic Disorders IMD
- Interventions
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2018-11-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT02715505
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant
Phase 2
Completed
- Conditions
- Single Umbilical Cord Blood TransplantationNon-myeloablative ConditioningAcute Lymphocytic LeukemiaMyelodysplastic SyndromeNon-Hodgkin's LymphomaMultiple MyelomaChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT01930162
- Locations
- 🇺🇸
Novartis Investigative Site, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath